Featured Publications
Sex Differences across Retrospective Transitions in Posttraumatic Stress and Substance Use Disorders
Peltier MR, Roberts W, Verplaetse TL, Zakiniaeiz Y, Burke C, Moore KE, McKee SA. Sex Differences across Retrospective Transitions in Posttraumatic Stress and Substance Use Disorders. Journal Of Dual Diagnosis 2021, 18: 11-20. PMID: 34965199, PMCID: PMC9086923, DOI: 10.1080/15504263.2021.2016027.Peer-Reviewed Original ResearchConceptsDrug use disordersOngoing posttraumatic stress disorderSubstance use disordersSUD/PTSDPosttraumatic stress disorderNew PTSD diagnosisImpact of sexUse disordersDiagnosis of SUDPast-year substance use disorderPTSD diagnosisConcurrent substance use disordersDiagnosis of PTSDPoor treatment outcomesNational Epidemiologic SurveyBidirectional relationshipSex-specific analysesPotential sex-specific differencesTreatment outcomesRole of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review
Peltier MR, Sofuoglu M. Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review. CNS Drugs 2018, 32: 421-435. PMID: 29761343, PMCID: PMC6235727, DOI: 10.1007/s40263-018-0525-5.Peer-Reviewed Original ResearchConceptsSubstance use disordersExogenous progesteroneUse disordersTreatment of SUDsNovel pharmacological treatmentsFemale sex hormonesTreatment of menNovel pharmacological interventionsTobacco/nicotineFemale substance usersDrugs of abuseMetabolite allopregnanolonePharmacological treatmentPreliminary efficacySex hormonesPharmacological interventionsAvailable interventionsNovel treatmentsAllopregnanoloneEuphoric effectsProgesteroneNarrative reviewLiterature searchSubstance useSubstance users
2023
Examining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III
Fields L, Roberts W, Schwing I, McCoy M, Verplaetse T, Peltier M, Carretta R, Zakiniaeiz Y, Rosenheck R, McKee S. Examining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III. Drug And Alcohol Dependence Reports 2023, 7: 100162. PMID: 37159814, PMCID: PMC10163607, DOI: 10.1016/j.dadr.2023.100162.Peer-Reviewed Original ResearchTobacco use disorderSubstance use disordersBody mass indexUse disordersPsychiatric conditionsRisk of SUDAdditional substance use disordersSingle health conditionsRelated Conditions Wave IIIWorse health outcomesNational Epidemiological SurveyPsychiatric disorder diagnosisHarmful substance useDSM-5 criteriaConcurrent obesityComorbid obesityMass indexSUD diagnosisRisk factorsObesityComorbid diagnosesEpidemiological surveyHealth outcomesNESARC-IIIDisorder diagnosis
2020
Do Sex Differences Among Adults With Opioid Use Disorder Reflect Sex-specific Vulnerabilities? A Study of Behavioral Health Comorbidities, Pain, and Quality of Life.
Rhee TG, Peltier MR, Sofuoglu M, Rosenheck RA. Do Sex Differences Among Adults With Opioid Use Disorder Reflect Sex-specific Vulnerabilities? A Study of Behavioral Health Comorbidities, Pain, and Quality of Life. Journal Of Addiction Medicine 2020, 14: 502-509. PMID: 32371659, PMCID: PMC8962823, DOI: 10.1097/adm.0000000000000662.Peer-Reviewed Original ResearchConceptsPast-year opioid use disorderOpioid use disorderSubstance use disordersUse disordersTreatment of OUDPast-year substance use disorderBehavioral health comorbiditiesPast-year psychiatric disordersSex differencesHealth-related qualityRelated Conditions Wave IIIBehavioral health conditionsNon-institutionalized adultsLogistic regression analysisQuality of lifeNational Epidemiological SurveyDSM-5 criteriaSocio-demographic factorsHealth comorbiditiesConcurrent disordersUS adultsPsychiatric disordersDiagnostic criteriaOUD statusWave IIIChapter 23 Pharmacological cognitive enhancers
Peltier M, Sofuoglu M. Chapter 23 Pharmacological cognitive enhancers. 2020, 303-320. DOI: 10.1016/b978-0-12-815298-0.00023-x.Peer-Reviewed Original ResearchSubstance use disordersSignificant health problemNovel pharmacological targetsSignificant cognitive deficitsChronic usePharmacological treatmentCandidate medicationsTreatment outcomesTreatment strategiesUse disordersHealth problemsPharmacological targetsCognitive deficitsCognitive enhancementSubstance useCognitive enhancersPotential mechanismsCognitive functioningTreatmentPharmacological cognitive enhancementPharmacological cognitive enhancersMedicationsImpairmentCocaine
2019
The prevalence of substance use disorders among community-based adults with legal problems in the U.S
Moore KE, Oberleitner L, Pittman BP, Roberts W, Verplaetse TL, Hacker RL, Peltier MR, McKee SA. The prevalence of substance use disorders among community-based adults with legal problems in the U.S. Addiction Research & Theory 2019, 28: 165-172. PMID: 32952490, PMCID: PMC7500665, DOI: 10.1080/16066359.2019.1613524.Peer-Reviewed Original ResearchDrug use disordersSubstance use disordersAlcohol use disorderUse disordersAlcohol-related legal problemsSUD diagnosisSystem involvementAUD diagnosisCurrent AUD diagnosisCurrent alcohol use disorderLifetime alcohol use disorderNational prevalence estimatesStimulant use disorderCommunity-based adultsJustice system involvementLifetime AUD diagnosisDUD diagnosesPrevalence estimatesDiagnosisDisordersAdultsDSM-5Continued needIntervention effortsRepresentative U.S. sample